The technology, an electromagnetic navigation bronchoscope, is used to diagnose pulmonary diseases like emphysema, cancer and tuberculosis, using a technology based on electromagnetic tracking, image processing and endoscopy. The system won CE Mark approval in the European Union in 2002 and 510(k) clearance from the FDA in 2004.
Mansfield, Mass.-based Covidien paid $300 million for Israel’s superDimension in March 2012.
"As the number of people with lung cancer increases, the value of effective tools to support the physician in aiding in diagnoses becomes increasingly more important," Dr. Kyle Hogarth of the The University of Chicago said in prepared remarks. "Even a minor shift in finding people at Stage 1 or Stage 2 may dramatically change the societal impact of lung cancer."
"Covidien partnered with pulmonologists to redesign the superDimension software and introduce new biopsy tools to improve patient outcomes. This latest version of the superDimension software allows me to find tumors sooner by reducing the case planning time required prior to a procedure, simplifying the navigation process, and enhancing the visualization," Hogarth added.
"These advanced tools and technologies demonstrate Covidien’s commitment to expanding the specialized lung health products available to pulmonologists and thoracic surgeons," Covidien early technologies president Chuck Brynelsen said in a statement. "We continue to create a comprehensive portfolio of instruments and technologies designed to help the physician improve how lung cancer is diagnosed with the ultimate goal of improving patient health."